* Entera Bio Ltd ENTX.OQ ENTX.O is expected to show no
change
in quarterly revenue when it reports results on May 3
(estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Entera Bio Ltd is for a
loss
of 6 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Entera Bio
Ltd is
$10.00, above its last closing price of $1.96.
This summary was machine generated May 1 at 11:53 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)